Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emicizumab Data Has Shire And Novo Looking Over Their Shoulders

Executive Summary

Positive data from the HAVEN 1 Phase III study of Genentech's emicizumab put pressure on the hemophilia franchises of both Shire and Novo Nordisk.

Advertisement

Related Content

Competition Coming For Hemophilia Franchises, But Will Patients And Payers Embrace New Drugs?
Shire's Record Year Bolstered By Baxalta, But Shows Across-The-Board Growth
Stockwatch: Mistaken Acquisitions Dim Earnings Season
Novo Nordisk 'Caught Short' By Lantus Exclusion
Shire Builds Confidence In $20bn Revenue Target

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097923

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel